SCHEMBL5490712

SCHEMBL5490712

CCS(=O)(=O)c1cccc(C(=O)O)c1N

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CASP7 P55210 2/20 0.50
ALOX15 P16050 2/20 0.50
G6PD P11413 1/20 0.50
CASP6 P55212 1/20 0.50
TSHR P16473 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
CA12 O43570 5/20 0.46
CA9 Q16790 5/20 0.46
F2 P00734 3/20 0.42
PRSS1 P07477 3/20 0.42
PRSS2 P07478 3/20 0.42
PRSS3 P35030 3/20 0.42
MMP2 P08253 2/20 0.42
CA1 P00915 1/20 0.42
CA2 P00918 1/20 0.42
MMP1 P03956 1/20 0.42
MMP9 P14780 1/20 0.42
MMP8 P22894 1/20 0.42
MMP13 P45452 1/20 0.42
APEX1 P27695 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9619019 0.85 CA12 (0.50) CASP7ALOX15G6PDCASP6TSHR
SCHEMBL10424214 0.83 G6PD (0.47) CASP7ALOX15G6PDCASP6TSHR
Acetic Acid SCHEMBL9659072 0.83 ALOX15 (0.44) CASP7ALOX15G6PDCASP6TSHR
SCHEMBL9618785 0.82 TSHR (0.73) CASP7ALOX15G6PDCASP6TSHR
SCHEMBL7707773 0.82 G6PD (0.57) CASP7ALOX15G6PDCASP6TSHR
SCHEMBL5724579 0.82 TSHR (0.68) ALOX15TSHRSMN1; SMN2CA12CA9
SCHEMBL1829605 0.81 TSHR (0.49) CASP7ALOX15TSHRSMN1; SMN2CA12
SCHEMBL524233 0.80 CASP7 (0.55) CASP7ALOX15G6PDCASP6TSHR
SCHEMBL3951462 0.80 G6PD (0.60) CASP7ALOX15G6PDCASP6TSHR
SCHEMBL9659068 0.79 CA2 (0.46) CASP7ALOX15G6PDCASP6TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070270496-A1 Pharmaceutical composition for the treatment of pathologies caused by the general response of the immune system EPITECH GROUP S.R.L. (IT) 2007-11-22 US claimed
EP-1844784-A1 A pharmaceutical composition for the treatment of pathologies caused by the general response of the immune system Epitech Group S.r.l. (IT) 2007-10-17 EP claimed
US-20040220356-A1 Compositions for golf equipment JPMORGAN CHASE BANK, N.A., AS SUCCESSOR ADMINISTRATIVE AGENT 2004-11-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070270496-A1 Pharmaceutical composition for the treatment of pathologies caused by the general response of the immune system HCAR2, HCAR1, MYD88 CASP7 2088/4885ALOX15 97/4885G6PD 2157/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.